Unicycive Therapeutics, Inc. (UNCY)
UNCY moved a median of -0.23% 30 minutes after news, and +0.23% by the close. How UNCY actually reacts to news — the realized, point-in-time move the market made, measured across 999 labeled events over the last three years with zero look-ahead.
UNCY’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | 0.00% | 45% | 978 |
| 30-min | -0.23% | 39% | 990 |
| 60-min | -0.23% | 43% | 990 |
| to close | +0.23% | 52% | 978 |
| Middle 50% of UNCY reactions | -1.48% to +0.74% |
|---|---|
| Median reaction (30-min) | -0.23% |
| Measured reactions | 999 |
Half of all Unicycive Therapeutics, Inc. news events land between -1.48% and +0.74% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
How UNCY reacts, by analyst action.
| Event | Events | Median 30-min | % positive | Median to close |
|---|---|---|---|---|
| Coverage initiations | 17 | -0.20% | 47% | -1.67% |
| Rating reiterations | 70 | -0.05% | 41% | -0.21% |
Last 3 years, pulled 2026-09-21. Reaction = percent move vs. the price at the news timestamp. Counts and medians only. The same measurement runs across every name in the dataset. 4 further classes were observed with fewer than 10 measured events and are not published. See how UNCY ranks against every other measured name →
That’s how UNCY usually reacts — get an email when it moves on news →Email me when UNCY moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to UNCY's baseline. Nothing else.
Recent UNCY events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Unicycive Therapeutics Announces FDA Acceptance of Oxylanthanum Carbonate New Drug Application Resubmission and PDUFA Date of March 25, 2027 | Press release | GlobeNewswire | — | — | |
| Kaplan Fox & Kilsheimer LLP Encourages Unicycive Therapeutics, Inc. (NASDAQ:UNCY) Investors to Contact the Firm Before November 2, 2026 | Press release | ACCESS Newswire | -0.25% | +0.98% | |
| Unicycive Therapeutics Appoints Meredith Manning to Board of Directors | Press release | GlobeNewswire | +0.21% | -3.40% | |
| Form 8-K Unicycive Therapeutics, For: Sep 28 | SEC filing · Form 8-K | SEC EDGAR | -5.95% | -2.36% | |
| Unicycive Therapeutics Announces Resubmission of New Drug Application for Oxylanthanum Carbonate | Press release | GlobeNewswire | -5.95% | -2.36% | |
| Form 8-K Unicycive Therapeutics, For: Sep 03 | SEC filing · Form 8-K | SEC EDGAR | -5.95% | -2.36% | |
| Unicycive Therapeutics, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights – UNCY | Press release | Business Wire | -1.85% | -1.95% | |
| Unicycive Therapeutics to Present at the H.C. Wainwright 28th Annual Global Investment Conference | Press release | GlobeNewswire | +1.17% | -1.56% | |
| Form 10-Q Unicycive Therapeutics, For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | +0.97% | +4.86% | |
| Form 8-K Unicycive Therapeutics, For: Aug 12 | SEC filing · Form 8-K | SEC EDGAR | +0.97% | +4.86% | |
| Unicycive Therapeutics Announces Second Quarter 2026 Financial Results and Provides Business Update | Press release | GlobeNewswire | +0.97% | +4.86% | |
| Bronstein, Gewirtz & Grossman, LLC Is Investigating Bronstein, Gewirtz & Grossman, LLC (UNCY) And Encourages Stockholders to Connect | Press release | ACCESS Newswire | -0.92% | -0.37% | |
| Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Unicycive Therapeutics, Inc. (UNCY) And Encourages Shareholders to Reach Out | Press release | ACCESS Newswire | -0.45% | -1.27% | |
| Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Unicycive Therapeutics, Inc. (UNCY) and Encourages Shareholders to Learn More About the Investigation | Press release | ACCESS Newswire | +0.53% | -1.24% | |
| Bronstein, Gewirtz & Grossman, LLC Encourages Unicycive Therapeutics, Inc. (UNCY) Shareholders to Inquire about Securities Investigation | Press release | ACCESS Newswire | +0.00% | +2.44% | |
| Bronstein, Gewirtz & Grossman, LLC Encourages Unicycive Therapeutics, Inc. (UNCY) Stockholders to Inquire about Securities Investigation | Press release | ACCESS Newswire | -0.39% | +4.46% | |
| Unicycive Therapeutics, Inc. (UNCY) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation | Press release | ACCESS Newswire | +0.00% | -4.01% | |
| Bronstein, Gewirtz & Grossman, LLC Is Investigating Unicycive Therapeutics, Inc. (UNCY) And Encourages Stockholders to Connect | Press release | ACCESS Newswire | -0.49% | -0.10% | |
| Unicycive Therapeutics, Inc. (UNCY) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation | Press release | ACCESS Newswire | -1.93% | -1.93% | |
| Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Unicycive Therapeutics, Inc. (UNCY) and Encourages Stockholders to Learn More About the Investigation | Press release | ACCESS Newswire | +0.00% | +0.00% | |
| Bronstein, Gewirtz & Grossman, LLC Encourages Unicycive Therapeutics, Inc. (UNCY) Investors to Inquire about Securities Investigation | Press release | ACCESS Newswire | +0.46% | -2.59% | |
| Form 8-K Unicycive Therapeutics, For: Jul 02 | SEC filing · Form 8-K | SEC EDGAR | -1.27% | +3.62% | |
| Unicycive Therapeutics Receives Complete Response Letter from FDA Regarding Resubmitted Oxylanthanum Carbonate (OLC) New Drug Application (NDA) | Press release | GlobeNewswire | +7.00% | +17.25% | |
| Form 8-K Unicycive Therapeutics, For: Jun 19 | SEC filing · Form 8-K | SEC EDGAR | +8.67% | +12.91% | |
| Form DEFA14A Unicycive Therapeutics, | SEC filing · Form DEFA14A | SEC EDGAR | +8.67% | +12.91% | |
| Form EFFECT Unicycive Therapeutics, | SEC filing · Form EFFECT | SEC EDGAR | +2.11% | +0.70% | |
| Form 8-K Unicycive Therapeutics, For: Jun 05 | SEC filing · Form 8-K | SEC EDGAR | -1.21% | -4.86% | |
| Form S-3 Unicycive Therapeutics, | SEC filing · Form S-3 | SEC EDGAR | -1.21% | -4.86% | |
| Form 10-Q Unicycive Therapeutics, For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | +0.63% | +2.77% | |
| Form 8-K Unicycive Therapeutics, For: May 12 | SEC filing · Form 8-K | SEC EDGAR | +0.63% | +2.77% | |
| Unicycive Therapeutics Announces First Quarter 2026 Financial Results and Provides Business Update | Press release | GlobeNewswire | +0.63% | +2.77% | |
| Form S-8 Unicycive Therapeutics, | SEC filing · Form S-8 | SEC EDGAR | -3.00% | -0.61% | |
| Form ARS Unicycive Therapeutics, For: Dec 31 | SEC filing · Form ARS | SEC EDGAR | +1.80% | +5.95% | |
| Form DEF 14A Unicycive Therapeutics, For: Jun 19 | SEC filing · Form DEF | SEC EDGAR | +1.80% | +5.95% | |
| Form DEFA14A Unicycive Therapeutics, | SEC filing · Form DEFA14A | SEC EDGAR | +1.80% | +5.95% | |
| Unicycive Therapeutics to Present at the 25th Annual Needham Virtual Healthcare Conference | Press release | GlobeNewswire | +0.62% | +3.42% | |
| Bronstein, Gewirtz & Grossman, LLC Encourages Unicycive Therapeutics, Inc. (UNCY) Shareholders to Inquire about Securities Investigation | Press release | ACCESS Newswire | +0.46% | +1.37% | |
| Form 8-K Unicycive Therapeutics, For: Apr 06 | SEC filing · Form 8-K | SEC EDGAR | +2.88% | -4.75% | |
| Bronstein, Gewirtz & Grossman, LLC Is Investigating Unicycive Therapeutics, Inc. (UNCY) And Encourages Shareholders to Connect | Press release | ACCESS Newswire | +2.88% | -4.75% | |
| Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Unicycive Therapeutics, Inc. (UNCY) And Encourages Shareholders to Reach Out | Press release | ACCESS Newswire | -0.36% | -0.43% | |
| Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Unicycive Therapeutics, Inc. (UNCY) and Encourages Shareholders to Learn More About the Investigation | Press release | ACCESS Newswire | +0.70% | +2.33% | |
| Form 10-K Unicycive Therapeutics, For: Dec 31 | SEC filing · Form 10-K | SEC EDGAR | +0.65% | -0.81% | |
| Form 8-K Unicycive Therapeutics, For: Mar 30 | SEC filing · Form 8-K | SEC EDGAR | +0.65% | -0.81% | |
| Unicycive Therapeutics Announces Full Year 2025 Financial Results and Provides Business Update | Press release | GlobeNewswire | +0.65% | -0.81% | |
| Bronstein, Gewirtz & Grossman, LLC Encourages Unicycive Therapeutics, Inc. (UNCY) Stockholders to Inquire about Securities Investigation | Press release | ACCESS Newswire | +0.65% | -0.81% | |
| Unicycive Therapeutics, Inc. (UNCY) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation | Press release | ACCESS Newswire | -0.30% | -2.89% | |
| Bronstein, Gewirtz & Grossman, LLC Encourages Unicycive Therapeutics, Inc. (UNCY) Stockholders to Inquire about Securities Investigation | Press release | ACCESS Newswire | +0.00% | +0.44% | |
| Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Unicycive Therapeutics, Inc. (UNCY) And Encourages Stockholders to Reach Out | Press release | ACCESS Newswire | +0.71% | -0.85% | |
| Bronstein, Gewirtz & Grossman, LLC Is Investigating Unicycive Therapeutics, Inc. (UNCY) And Encourages Stockholders to Connect | Press release | ACCESS Newswire | +0.87% | +1.74% | |
| Unicycive Therapeutics, Inc. (UNCY) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation | Press release | ACCESS Newswire | +0.58% | +1.45% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the UNCY section they belong to.
Where else UNCY is measured.
UNCY earnings → · Analyst actions → · SEC filings →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is Unicycive Therapeutics, Inc.'s median reaction calculated?
Every labeled UNCY news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 999 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 39% of UNCY's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does UNCY's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.